

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Service Category:

- | | |
|--|---|
| <input type="checkbox"/> Anesthesia | <input type="checkbox"/> Medicine Services and Procedures |
| <input type="checkbox"/> Surgery | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures | <input type="checkbox"/> DME/Prosthetics or Supplies |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Other: Part B Drugs |

Service Description:

This document addresses the use of imetelstat (Rytelo®), an oligonucleotide telomerase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). Rytelo is administered by intravenous infusion only over a period of 2 hours.

Background Information:

Myelodysplastic syndromes (MDS) are a group of heterogeneous hematologic malignancies characterized by clonal abnormalities in blood cell production, leading to cytopenias, abnormal cellular maturation, and varying risks of progression to acute myeloid leukemia (AML). While many patients with MDS exhibit symptoms such as anemia, bleeding, or infections, others may remain asymptomatic.

The prognosis for MDS patients varies significantly, with outcomes largely determined by specific bone marrow, blood, cytogenetic, and molecular features. Patients are generally classified into lower-risk or higher-risk categories based on these features, guiding treatment strategies accordingly. The Revised International Prognostic Scoring System assigns a score of ≤ 3.5 to classify lower-risk MDS patients.

Most MDS cases fall into the "lower-risk" category (LR-MDS), signifying a reduced immediate risk of death or progression to AML. However, anemia and complications from cytopenias, transfusions, and inflammation can adversely impact comorbidities, potentially lowering quality of life (QoL) and increasing mortality compared to the general population. After diagnosing and assessing risk, treatment is individualized, with the focus for LR-MDS patients on managing symptoms and enhancing QoL. Given the typically long survival with malignant hematopoiesis, treatment often centers on addressing cytopenias—particularly anemia—and managing complications like iron overload.

A major complication in LR-MDS is progressive anemia, eventually necessitating regular red blood cell (RBC) transfusions. Erythropoiesis-stimulating agents (ESAs) are the standard first-line treatment for symptomatic anemia in LR-MDS, as they stimulate RBC production in the bone marrow. However, response rates to ESAs vary widely, with 30-60% of patients responding for 1-2 years. Over time, all patients eventually become resistant to ESA therapy. Those with low RBC transfusion needs and serum erythropoietin (sEPO) levels below 200-500 mU/mL are more likely to respond to ESAs, whereas patients with high transfusion requirements or sEPO levels above 500 mU/mL have a significantly lower likelihood (<10%) of achieving a response.

Imetelstat (Rytelo), a telomerase inhibitor, has received FDA approval for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who suffer from transfusion-dependent anemia and require at least four red blood cell (RBC) units over eight weeks. This approval is specifically for those who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). The approval

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

was granted based on the phase 3 IMerge trial (NCT02598661), a double-blind, multicenter, placebo-controlled study.

The IMerge trial involved 178 patients (aged ≥ 18 years) with low or intermediate-1 risk MDS, categorized according to the International Prognostic Scoring System (IPSS) criteria, who were either ESA-relapsed, ESA-refractory, or ESA-ineligible. Participants were randomized to receive either imetelstat (118 patients) or a placebo (60 patients) until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the achievement of an 8-week period of RBC transfusion independence (RBC-TI), defined as the absence of RBC transfusions for at least eight consecutive weeks from randomization until any subsequent anti-cancer therapy.

The median follow-up was 19.5 months for the imetelstat group and 17.5 months for the placebo group. The results showed that 40% of patients in the imetelstat group achieved RBC-TI for at least eight weeks, compared to 15% in the placebo group, highlighting a significant difference in efficacy (rate difference 25%; $p=0.0008$). Additionally, RBC transfusion independence lasting at least 24 weeks was achieved by 28.0% of imetelstat-treated patients (95% CI, 20.1%-37.0%) compared to 3.3% in the placebo group (95% CI, 0.4%-11.5%; $P < .001$). The median duration of RBC-TI was approximately one year for 8-week responders and 1.5 years for 24-week responders in the imetelstat group.

Subgroup analysis revealed that among patients with serum erythropoietin (sEPO) levels greater than 500 mU/mL, 26.9% achieved RBC-TI at 8 weeks with imetelstat (vs. 9.1% with placebo; $P = .107$), and 15.4% achieved RBC-TI at 24 weeks (vs. 0.0% with placebo; $P = .050$). However, safety data indicated that 91% of patients treated with imetelstat experienced grade 3-4 treatment-emergent adverse events, compared to 47% of patients receiving placebo. The most common adverse events in the imetelstat group were neutropenia (68% vs. 3% in the placebo group) and thrombocytopenia (62% vs. 8% in the placebo group).

Approved Indications

- A. Imetelstat (Rytelo®) is indicated by the FDA for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

Other Uses

- A. None.

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Imetelstat (Rytelo®)

A. Criteria For Initial Approval (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

- i. Individual is 18 years of age or older; **AND**
- ii. Individual meets one of the following (A or B or C):
 - A. The patient has myelodysplastic syndrome (MDS) that is classified as low- to intermediate-1 risk, **AND**
 - 1. Documentation is provided that individual is transfusion-dependent anemia requiring four (4) or more red blood cell units over eight (8) weeks in the last sixteen (16) weeks; **AND**
 - 2. Documentation is provided that individual is relapsed, refractory, or is ineligible for erythropoiesis-stimulating (ESA) agents; **AND**
 - 3. Individual meets **one** of the following:
 - a. International Prognostic Scoring System (IPSS): Low or intermediate-1 risk (defined as a score of 0 to 1); **OR**
 - b. Revised International Prognostic Scoring System (IPSS-R): Very low, low, intermediate risk (defined as a score of 0 to 4.5); **OR**
 - c. WHO-Based Prognostic Scoring System (WPSS): very low, low, intermediate (Score 0 to 2);

OR

- B. Individual has a diagnosis of lower risk myelodysplastic syndromes (MDS) with symptomatic anemia and no del(5q) abnormalities (NCCN 2A); **AND**
 - 1. Individual has ring sideroblasts 15% or greater (or ring sideroblasts 5% to 14% with an SF3B1 mutation); **AND**
 - a. Documentation is provided that individual has serum erythropoietin greater than 500mU/mL (i.e. ineligible for ESA);
 - OR**
 - b. Documentation is provided that individual has no response or relapse after luspaterceptaamt therapy;
 - 2. Documentation is provided that individual has ring sideroblasts less than 15% (or ring sideroblasts less than 5% with an SF3B1 mutation) and serum erythropoietin greater than 500 mU/mL with no response, intolerance, relapse, or poor probability of response to immunosuppressive therapy;

OR

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

3. Individual has ring sideroblasts less than 15% (or ring sideroblasts less than 5% with an SF3B1 mutation) and serum erythropoietin 500 mU/mL or less; **AND**
 - a. Documentation is provided that individual has no response or relapse after ESA or luspatercept-aamt therapy;

OR

- C. Individual has a diagnosis lower risk myelodysplastic syndromes (MDS) with symptomatic anemia with del(5q) abnormalities (NCCN 2A); **AND**
 1. Documentation is provided that individual has no response to or relapse after lenalidomide or ESA; **AND**
 2. Individual has poor probability of response to immunosuppressive therapy; **OR**
 3. Individual has no response to intolerance, or relapse after immunosuppressive therapy;

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of imetelstat (Rytelo®) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when the following evidence is submitted:
 - A. The patient has experienced a decrease in red blood cell (RBC) transfusion burden after 24 weeks (6 months of therapy); **AND**
 - B. The patient has not experienced unacceptable toxicity.

C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Anemia not related to LR-MDS; **OR**
- ii. Individual has not responded (response defined as decrease in transfusion burden from baseline) after 24 weeks of treatment (i.e. Administration of 6 doses consecutively) at maximum dose level (i.e. 7.1 mg/kg every 4 weeks); **OR**
- iii. Individual has hemoglobin higher than 12 g/dL (NCCN 2A); **OR**
- iv. When the above criteria are not met, and for all other indications.

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosing Schedule
imetelstat (Rytelo®) 47 mg, 188 mg single-dose vial	<ul style="list-style-type: none"> • 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks.
Exceptions	
None	

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
C93.10	Chronic myelomonocytic leukemia not having achieved remission
D46.0	Refractory anemia without ring sideroblasts
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.4	Refractory anemia, unspecified
D46.9	Myelodysplastic syndrome, unspecified
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.Z	Other myelodysplastic syndromes

HCPCS Codes:

Codes	Description
J0870	Injection, imetelstat, 1 mg [Rytelo]

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Reference Information:

1. Brunner, A.M., Leitch, H.A., van de Loosdrecht, A.A. *et al.* Management of patients with lower-risk myelodysplastic syndromes. *Blood Cancer J.* 12, 166 (2022). <https://doi.org/10.1038/s41408-022-00765-8>
2. Hattakitpanitchakul S, Kobbuaklee S, Wudhikarn K, Polprasert C. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes. *Asian Pac J Cancer Prev.* 2021 Dec 1;22(12):4037-4042. doi: 10.31557/APJCP.2021.22.12.4037. PMID: 34967586; PMCID: PMC9080375.
3. Meunier M, Park S. Lower-risk myelodysplastic syndromes: Current treatment options for anemia. *EJHaem.* 2022 Aug 12;3(4):1091-1099. doi: 10.1002/jha2.523. PMID: 36467818; PMCID: PMC9713208.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Geron Corporation. (n.d.). *Rytelo (imetelstat) prescribing information*. Retrieved March 30, 2026, from https://pi.geron.com/products/US/pi/rytelo_pi.pdf
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
7. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 11, 2025.
 - a. Myelodysplastic Syndromes. Version 2.2025. Revised January 17, 2025.
8. Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2024;403(10423):249-260. doi:10.1016/S0140-6736(23)01724-5
9. Sekres MA, Platzbecker U. Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS. UptoDate. Last update 06/11/2024.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

Policy Name: Imetelstat (Rytelo)	Policy Number: MP-RX-FP-157-24	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 10/8/2024 Last Review Date: 5/6/2026	Effective Date: 5/6/2026 Frequently Revision: Annual
--	--	--	---	---

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Updated criteria for Initial Approval to add criteria for lower risk myelodysplastic syndromes per NCCN, formatting. Updated Conditions not Covered. Administrative update to add documentation and incorporate new policy template. Added available dosage forms and updated references. Coding Reviewed: no changes.	5/1/2026	5/6/2026
Annual Review	Minimal changes; word formatting. Update J-code for rytelo: J0870 Injection, imetelstat, 1 mg [Rytelo].	6/9/2025	6/19/2025
Policy Inception	New Medical Policy creation.	9/16/2024	10/8/2024